Long-Term Persistence and Effectiveness of Risankizumab in Multi-Refractory Psoriatic Arthritis: A 16-Center Real-World Registry (SKYREAL) (ACR Convergence 2026) - Sep 8, 2026 - Abstract #363; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "In the largest real-world rheumatology cohort of risankizumab in PsA to date, the drug showed high long-term persistence and robust, sustained efficacy in heavily pretreated patients, with a favorable safety profile. Baseline articular disease activity (DAPSA) was the principal predictor of early discontinuation, supporting closer monitoring of high-activity patients during the first year. Continuous variables: mean ± SD; categorical: n (%)."
Clinical • Real-world • Real-world evidence • Cardiovascular • Immunology • Infectious Disease • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Urticaria • CRP • IL17A
|
|
Maria Vanesa Hernández Hernández1; Antonio Álvarez de Cienfuegos2; Isabel Peinado Ruiz3; Luis Gómez-Lechón Quirós4; Vicente Aldasoro5; Maria Laino6; Marilo Toledo7; Blanca Viejo7; Alba Belmonte-Mora8; Enrique Raya9; BEATRIZ JOVEN10; Cristina Valero-Martínez11; Cristina Campos Fernández12; Jesús Cerdeña Corrales13; Isabel Martinez Cordellat12; Cristina Martinez Gonzalez14; Hiurma Sanchez-Perez14; Carmen Carrasco Cubero15; Laura Nuño16; Diana Peiteado17; Pablo Rodriguez-Merlos18; Ana Belen Azuaga19; Julio Ramírez20; Enrique González Dávila21; Federico Diaz-Gonzalez14
|